Combined molecular biology test can identify patients with benign pancreatic abnormalities

FDA approves pancreatic cancer device

FDA approved a first-of-its-kind device for the treatment of adult patients with locally advanced pancreatic cancer. Optune Pax, developed by Novocure, is a portable, non-invasive device that delivers alternating electrical fields, known as tumor treating fields, to the abdomen.

February 20, 2026

Vol.52 No.07

Clinical Roundup

Immunity against CMV leveraged against pancreatic cancer in study by UCSD, La Jolla Institute of Immunology

Researchers at the University of California San Diego and La Jolla Institute of Immunology have discovered a promising treatment approach for pancreatic cancer, one of the deadliest and most treatment-resistant forms of cancer. The approach leverages the body’s natural immune response to cytomegalovirus, a common but typically harmless virus that most people are infected with at some point in their lives.

February 13, 2026

Vol.52 No.06

Clinical Roundup

Cedars-Sinai researchers develop risk score to help predict pancreatic cancer recurrence

Cedars-Sinai investigators, leading a multi-institutional team, have developed and validated a tool to predict which patients with pancreatic neuroendocrine tumors need closer monitoring because their cancer is more likely to recur.

December 19, 2025

Vol.51 No.46

Clinical Roundup

Targeted radiation during surgery reduces pancreatic cancer recurrence, Hopkins study finds

Using intraoperative radiation to eliminate pancreatic cancer cells that have spread to areas around the pancreas, investigators at Johns Hopkins have been able to reduce the recurrence rate around the pancreas to 5%.

October 31, 2025

Vol.51 No.40

Cancer Policy

Revolution Medicines’ pancreatic cancer drug received a new priority voucher from FDA

Earlier this year, FDA announced that it would be initiating a voucher program aimed at accelerating review time for applications that are deemed to be advancing U.S. “national priorities” (The Cancer Letter, June 20, 2025).

October 24, 2025

Vol.51 No.39

By Claire Marie Porter

Clinical Roundup

Nanoparticle vaccine prevents melanoma, pancreatic, and breast cancers in mice, study finds

A study led by University of Massachusetts Amherst researchers demonstrates that their nanoparticle-based vaccine can effectively prevent melanoma, pancreatic, and triple-negative breast cancer in mice.

October 17, 2025

Vol.51 No.38

Combined molecular biology test can identify patients with benign pancreatic abnormalities

YOU MAY BE INTERESTED IN

FDA approves pancreatic cancer device

Immunity against CMV leveraged against pancreatic cancer in study by UCSD, La Jolla Institute of Immunology

Cedars-Sinai researchers develop risk score to help predict pancreatic cancer recurrence

Targeted radiation during surgery reduces pancreatic cancer recurrence, Hopkins study finds

Revolution Medicines’ pancreatic cancer drug received a new priority voucher from FDA

Nanoparticle vaccine prevents melanoma, pancreatic, and breast cancers in mice, study finds

Renew today!

Subscriber content

Never miss an issue!

Login